Indian stocks: Visit www.stage2stocks.com →

Scinai Immunotherapeutics Ltd.

Stage 4 · Declining · week 80

As of Oct 22, 2026, Scinai Immunotherapeutics is in Stage 4, the downtrend phase, now in week 80 (since Mar 24, 2025). It closed at $0.61, 95.9% below its 52-week high and below its 200-day average, which is falling.

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. More about the company

$0.61
+0.16% today
$826,686 · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SCNI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 53w
S4 17w
S4 83w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 53w → S1 6w → S4 17w → S1 7w → S4 83w current
Total tracked: 166 weeks across 5 stage runs.

SCNI among Biotechnology529th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…529SCNIStage 4 · wk 805−69.1%
vs 52W High
-95.9%
$0.61 lo$15.00 hi
95.9% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 80
1w13w26w
Week 80, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-87.0%
200 DMA: $4.69 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.05x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-69.1%
3M
-73.4%
6M
-86.6%
YTD
-91.6%
1Y
-96.0%
Scan Membership
Breakout Watch
Latest: 2020-05-05
3 appearances in last 60 days. First seen: 2019-04-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 80 · Vol 0.05x
2026-10-21S4
Wk 80 · Vol 0.07x
2026-10-20S4
Wk 80 · Vol 0.05x
2026-10-19S4
Wk 80 · Vol 0.04x
2026-10-16S4
Wk 79 · Vol 0.08x
2026-10-15S4
Wk 79 · Vol 0.14x
2026-10-14S4
Wk 79 · Vol 1.02x
2026-10-13S4
Wk 79 · Vol 46.14x
2026-10-12S4
Wk 79 · Vol 0.03x
2026-10-09S4
Wk 78 · Vol 0.01x
2026-10-08S4
Wk 78 · Vol 0.06x
2026-10-07S4
Wk 78 · Vol 0.03x
Moving averages & range
50 DMA
$1.77
200 DMA
$4.69
52W High
$15.00
52W Low
$0.61
5D Low
$0.61
Resistance levels (recent highs)
20d High
$1.55
60d High
$3.22
120d High
$6.45
250d High
$15.00
Next resistance
+153.7%
to 20d High
P/E (TTM)
0.0
Forward —
ROE
-26.5%
Profit margin -174.8%
Dividend Yield
0.00%
P/B 0.1

Scinai Immunotherapeutics: quick answers

What stage is Scinai Immunotherapeutics in?

As of Oct 22, 2026, Scinai Immunotherapeutics (SCNI) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 24, 2025 and is in week 80. What the four stages mean

Is Scinai Immunotherapeutics in an uptrend?

No. Scinai Immunotherapeutics is in a Stage 4 downtrend. It trades 87.0% below its 200-day average, which is falling.

How far is Scinai Immunotherapeutics from its 52-week high?

Scinai Immunotherapeutics closed at $0.61 on Oct 22, 2026, 95.9% below its 52-week high of $15.00. Its 52-week low is $0.61.

How has Scinai Immunotherapeutics performed over the past year?

As of Oct 22, 2026, Scinai Immunotherapeutics is down 96.0% over the past year and down 91.6% so far in 2026.

Which sector and industry is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.